Biohaven Pharmaceutical Holding ROA 2016-2022 | BHVN

Current and historical return on assets (ROA) values for Biohaven Pharmaceutical Holding (BHVN) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
Biohaven Pharmaceutical Holding ROA - Return on Assets Historical Data
Date TTM Net Income Total Assets Return on Assets
2022-06-30 $-1.02B $1.39B -82.24%
2022-03-31 $-0.79B $1.37B -71.49%
2021-12-31 $-0.85B $1.08B -83.51%
2021-09-30 $-0.87B $1.13B -94.46%
2021-06-30 $-0.89B $0.85B -107.17%
2021-03-31 $-0.86B $1.00B -118.65%
2020-12-31 $-0.77B $0.69B -126.46%
2020-09-30 $-0.70B $0.78B -160.55%
2020-06-30 $-0.61B $0.42B -174.50%
2020-03-31 $-0.64B $0.53B -174.71%
2019-12-31 $-0.53B $0.00B -179.74%
2019-09-30 $-0.43B $0.44B -118.50%
2019-06-30 $-0.39B $0.49B -127.44%
2019-03-31 $-0.22B $0.25B -89.58%
2018-12-31 $-0.24B $0.29B -112.94%
2018-09-30 $-0.21B $0.20B -119.94%
2018-06-30 $-0.19B $0.24B -111.33%
2018-03-31 $-0.20B $0.13B -119.64%
2017-12-31 $-0.14B $0.15B -91.75%
2017-09-30 $-0.14B $0.19B -113.58%
2017-06-30 $-0.12B $0.21B -163.46%
2017-03-31 $-0.08B $0.06B -386.21%
2016-12-31 $-0.06B $0.03B -948.15%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $10.535B $0.463B
Biohaven Pharmaceutical is a commercial-stage biotechnology company focused on developing, and commercializing products, primarily in the fields of central nervous system diseases, including neurological and rare disorders.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $160.059B 9.71
GSK (GSK) United Kingdom $81.408B 9.78
Bio-Rad Laboratories (BIO.B) United States $15.412B 34.05
QIAGEN (QGEN) Netherlands $11.018B 18.45
Ginkgo Bioworks Holdings (DNA) United States $5.561B 0.00
Arcus Biosciences (RCUS) United States $1.821B 35.53
Myovant Sciences (MYOV) United Kingdom $1.600B 0.00
Emergent Biosolutions (EBS) United States $1.482B 8.59
Zymeworks (ZYME) Canada $0.390B 0.00
Enzo Biochem (ENZ) United States $0.120B 0.00
Gelesis Holdings (GLS) United States $0.104B 0.00
SQZ Biotechnologies (SQZ) United States $0.097B 0.00
Ambrx Biopharma (AMAM) United States $0.089B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00